Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2019 08:01 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

-- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to...
November 07, 2019 06:55 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria Phase 2 Study 206 Trial Demonstrates Substantial...
October 17, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting

NEWTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
September 16, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
September 11, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

NEWTON, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
August 29, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
August 07, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

-- Interim Data from Study 206 Demonstrated Substantial Treatment Effect in Patients with Enteric Hyperoxaluria and Advanced Chronic Kidney Disease, Including Robust Reductions in Both Urine and...
August 06, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
June 27, 2019 20:45 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock

NEWTON, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
June 21, 2019 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop

NEWTON, Mass., June 21, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...